Steven Fagien

Steven Fagien

Auto-generated profile, based on publicly available information

Steven Fagien

Private Practice, Boca Raton, Florida

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Plastic and Reconstructive Surgery
Verified
Journal Article
Open access
SFSteven Fagien
Steven Fagien
VBVince Bertucci
Vince Bertucci
EGErika von Grote
Erika von Grote
JMJay H. Mashburn
Jay H. Mashburn
Background: Injectable hyaluronic acid fillers are routinely used for correction of soft-tissue volume loss and facial rejuvenation. Product differentiation has primarily been based on the rheologic parameter known as elastic modulus (G′), although other physicochemical properties are being explored to characterize potential product performance. As clinical data regarding product performance are lacking, the practical experience of injectors provides a valuable bridge in the knowledge gap between product rheologic data and product use. Methods: Rheologic and physicochemical measurements (swelling factor and cohesion) were collected for 18 products. To observe the impact of G′ and hyaluronic acid concentration on swelling factor and cohesion, proportional relationships were evaluated. Contributing authors were queried regarding their G′-based selection of products when considering skin quality, degree of correction, injection depth, and anatomical location. Results: Relationships were observable between G′ and swelling factor and G′ and cohesion only when limited to products manufactured by the same crosslinking technology and the same concentration. No relationship between isolated hyaluronic acid concentration and swelling factor or cohesion was apparent. Although rheological parameters and the assumptions of ex vivo data translating to in vivo performance are oftentimes not completely aligned, in the clinical experience of the authors, in general, higher G′ products are better suited for thicker skin and deeper injection planes, whereas lower G′ products are better for more superficial planes, although exceptions to these trends are also made based on technical experience. Conclusions: While rheologic and physicochemical characteristics can vary widely between products and the methods and measurements of these parameters are often difficult to correlate, G′ represents a useful and consistent parameter for product differentiation. Understanding how to select products based on G′ is valuable knowledge for customizing injection plans and contributes to an optimal aesthetic outcome.

1 July 2002 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
SFSteven Fagien
Steven Fagien
The surgical approach to rejuvenation of the periorbita continues to evolve with the application of procedures that are safe and effective with a greater sensitivity of aesthetics. Most of the topics in the recent literature discuss improvements with techniques relating to the lower eyelid and midface. Improved surgical techniques of the upper periorbita have been mostly limited to advances in brow lifting. The most common and traditional approach to upper blepharoplasty has remained essentially unchanged and has not considered, to the same degree as in the lower periorbita, the actual changes that occur with age or more accurate surgical approaches toward rejuvenation. The author presents an overview of his personal view of the concepts relating to the aging upper periorbita and discusses his experiences with this procedure.

1 January 2007 in Dermatologic Surgery
Verified
Journal Article
Closed access
PDF file
SFSteven Fagien
Steven Fagien
SCSue Ellen Cox
Sue Ellen Cox
JFJ. Charles Finn
J. Charles Finn
WWW. Philip Werschler
W. Philip Werschler
JKJonathan W. Kowalski
Jonathan W. Kowalski
Global patient-reported outcomes do not evaluate specific aspects of treatment that are important to patients. The objective was to evaluate self-perception of age and specific outcomes that are important to patients receiving botulinum toxin type A or placebo for moderate to severe glabellar lines (using the Facial Line Outcomes Questionnaire to assess how much facial lines bother them, make them look older, detract from their facial appearance, prevent a smooth facial appearance, and make them look tired, stressed, or angry). In the double-blind phase of this 12-week study, 70 patients were randomly assigned to treatment with 20 U botulinum toxin type A (BOTOX Cosmetic) or placebo. At Week 4, those still with moderate or severe glabellar lines were offered open-label 20 U botulinum toxin type A. Median glabellar line severity was significantly lower after botulinum toxin treatment than after placebo. Compared with placebo, botulinum toxin also resulted in significantly superior patient assessments and a greater proportion of patients considering they looked younger than their current age. Botulinum toxin type A can achieve specific goals of treatment that are important to patients and help them feel that they look younger than their current age.

1 February 2010 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
SFSteven Fagien
Steven Fagien
One of the most common aesthetic and rejuvenative facial plastic surgical procedures performed is upper blepharoplasty. The traditional approaches to this procedure have been conceptually related to the removal of apparent "excess" tissue to enhance the visibility of the pretarsal region and reduce the upper eyelid irregularities and changes that occur with age. Many times, surgery has been performed both bilaterally and similarly on each side without extensive preoperative planning irrespective of the patient presentation and has commonly incorporated the removal of skin, orbicularis oculi muscle, and upper periorbital fat. The orbicularis oculi muscle is excised for a variety of reasons and has, in general, not been considered as an important component that mandates preservation or a potential means with which to further enhance outcomes by manipulation. If upper eyelid ptosis is also present, it may be treated by traditional methods of blepharoptosis repair. Despite this, patients are more often generally pleased with the obvious improvements after surgery with these traditional surgical procedures, yet the changes do not necessarily approach the youthful configuration in some individuals, the asymmetries that they had presented with may persist, and changes might occur that were not anticipated that may detract from the overall aesthetic result. A simple yet comprehensive approach to upper blepharoplasty that considers both the youthful or desired appearance and the management of upper eyelid asymmetries by preservation or selective treatment of the orbicularis oculi muscle and placement of the upper eyelid crease to improve aesthetic outcomes is presented in this article.

1 December 2004 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
SFSteven Fagien
Steven Fagien
During the past 10 years the primary focus for the aesthetic use of botulinum toxin has been directed to the treatment of dynamic facial lines. This agent has been shown to be very effective for the improvement of facial shape. The use of botulinum toxin type A for the correction of a variety of presentations of facial asymmetry has also been well established. The general principles regarding the counter-effects of facial muscle protagonists and antagonists and their potential effects on the position of facial soft-tissue regions apply here as well. Twenty-two patients received botulinum toxin type A for the temporary treatment of mild to moderate unilateral upper eyelid ptosis and aesthetic improvement of lower eyelid position, with favorable results. Although commonly related to a rare yet feared adverse consequence from the inappropriate application of botulinum toxin, its application for the treatment of upper eyelid ptosis, eyelid position, and other lid fissure asymmetries for aesthetic improvement is presented.

1 March 2013 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
SFSteven Fagien
Steven Fagien
CMCorey Maas
Corey Maas
DMDiane K. Murphy
Diane K. Murphy
JTJane A. Thomas
Jane A. Thomas
FBFrederick C. Beddingfield
Frederick C. Beddingfield
FGfor the Juvéderm Lips Study Group
for the Juvéderm Lips Study Group
Background: Juvéderm Ultra injectable gel (Allergan, Inc, Irvine, California) is approved in the United States to treat moderate to severe wrinkles and folds, such as nasolabial folds. It is also used to enhance the appearance of the lips. Objectives: The authors evaluated the safety and effectiveness of Juvéderm Ultra injectable gel for lip enhancement and assessed the utility of 3 new lip-specific effectiveness scales. Methods: In this multicenter study, 50 subjects received lip enhancement with Juvéderm Ultra injectable gel. The subjects were observed closely by the treating investigator and results were evaluated by a blinded independent rater and by subject self-assessment for up to 48 weeks to determine the durability of the effects. A validated lip fullness scale (LFS) was used for analysis. Treatment satisfaction was assessed by investigators and subjects using an 11-point scale. Results: At week 12, 71% of subjects had achieved their goals for lip fullness and had maintained improvement of at least 1 grade on the LFS, which greatly exceeded the a priori criterion of 40% for success. At week 24, improvement in lip fullness was still present for 56% of subjects. Satisfaction and goal achievement exceeded 90% for subjects as well as investigators. Common side effects were predominantly mild or moderate in intensity and resolved within 1 week in the majority of subjects. Conclusions: Juvéderm Ultra injectable gel is safe and effective for lip enhancement. Scales for assessing lip fullness provide an objective method to determine the effectiveness of treatment. Level of Evidence: 2